Sorrento Therapeutics, Inc.
|$442 M||Market Cap|
|15.2%||EBIT / EV|
|N/A||FCF / EV|
|276.3%||3yr Avg Revenue Growth|
Business Model Diligence
We do not yet have Business Model Diligence for this stock.
|The EBIT / Enterprise Value of 15.2% ranks as Very High.|
|Cannot calculate Free Cash Flow / Enterprise Value, company has negative Free Cash Flow.|
|The Return on Invested Capital Value of 25.6% ranks as Very High.|
|Cannot calculate Cash Return on Invested Capital, company has negative Free Cash Flow.|
|The 3 Year Average Revenue Growth Value of 276.3% ranks as Very High.|
|Near-term Financial Health appears to be Worrisome. The Current Ratio is 0.54.|
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.
|Valvoline Inc. (VVV)|
|Procter & Gamble Company (PG)|
|McDonald's Corporation (MCD)|
|Fiat Chrysler Automobiles N.V. (FCAU)|
|Baozun Inc Sponsored ADR Class A (BZUN)|
|Vector Group Ltd. (VGR)|
|New Stocks Added!|